Biotech entity
Every one of those 2 sits in a single category, pharma. AppLovin is the most frequent co-covered peer, appearing in 1 of the 2 tracked stories. The 154-day window averages about 0.1 stories each week. Each story carries 2 original sources on average, compared with 3.7 for the broader beat in this window.
Last mentioned: Aug 4, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 50 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Every one of those 2 sits in a single category, pharma. AppLovin is the most frequent co-covered peer, appearing in 1 of the 2 tracked stories. The 154-day window averages about 0.1 stories each week. Each story carries 2 original sources on average, compared with 3.7 for the broader beat in this window. Their average consequence score of 5.5 runs below the beat's 6.2 for that window. Veeva Systems appears in 2 tracked Biotech stories published from March 4, 2026 through August 4, 2026.
Computed from the 2 stories linked to this entity, with beat comparisons drawn from all 541 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Veeva Systems. Shared-story counts are live from our verified record — not editorial picks.
Veeva Systems (VEEV) fell 5.3% to $201.56 during a broader software rout triggered by the Federal Reserve’s hawkish dot plot. The life-sciences cloud leader faces the same rate-driven multiple compression as other SaaS names, but its pharma client base and mission-critical R&D applications may insulate revenue, creating a potential long-term entry point for biotech investors.
As market volatility persists in early 2026, Eli Lilly and Veeva Systems emerge as top growth picks driven by the obesity drug boom and AI integration. With Eli Lilly's tirzepatide securing its spot as the world's top-selling drug and new oral GLP-1s on the horizon, the pharmaceutical landscape is shifting toward tech-heavy, high-margin innovation.
Veeva Systems is linked from 2 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
